according to the American Cancer Society. Dostarlimab—known generically as Jemperli—was developed by GSK in partnership with the biotech firm AnaptysBio in 2014, as the company expanded into ...

according to the American Cancer Society. GSK, in its news release, cited statistics that the five-year survival rate of extensive-stage small cell lung cancer is 3% and that the median overall ...

GlaxoSmithKline (GSK) plans to take a blood cancer antibody ... pre-treated multiple myeloma patients, presented at the American Society for Hematology (ASH) conference, was therefore hotly ...

GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

GSK says it plans to seek FDA approval for ... How common is cervical cancer and how deadly? The American Cancer Society predicts that in 2007, there will be about 11,150 new U.S. cases of ...

Obermair calls for his fellow gynecological cancer surgeons to join him in interrogating current standards of practice.

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...